Logotype for Jupiter Life Line Hospitals Limited

Jupiter Life Line Hospitals (JLHL) Q3 25/26 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Jupiter Life Line Hospitals Limited

Q3 25/26 earnings summary

9 Jul, 2026

Executive summary

  • Dombivli hospital, a 500-bed facility, was completed ahead of schedule and on budget, with 200 beds operational initially and full operations set for mid-February 2026; OPD services to start in early February 2026.

  • Pune South project construction has started, Mira Road is under regulatory approval, and Bibwewadi (Pune) is in early construction with minimal CapEx so far.

  • Existing hospitals show steady operating momentum, with no major operational surprises except for a one-time labor code impact.

Financial highlights

  • Q3 FY26 total income: INR 366.5 crore, up 9.8% year-over-year; EBITDA: INR 83.4 crore, up 9.2% year-over-year; EBITDA margin: 22.8%.

  • Q3 PAT: INR 42.5 crore, down 18.7% year-over-year, impacted by a one-time labor code provision of INR 6.4 crore.

  • 9M FY26 total income: INR 1,111.9 crore, up 15.1% year-over-year; EBITDA: INR 254 crore, up 15.2% year-over-year; EBITDA margin: 22.8%.

  • 9M PAT: INR 143.9 crore, down 3.1% year-over-year, also impacted by labor code changes.

  • Q3 ARPOB: INR 68,000; 9M ARPOB: INR 66,800; 9M ALOS: 3.85 days; 9M occupancy: 61.9% to 67.5%.

Outlook and guidance

  • Dombivli hospital expected to be EBITDA-negative for the first two years, with break-even anticipated by end of year two.

  • Consolidated margins will face a drag due to Dombivli's ramp-up; mature hospitals expected to maintain stable margins, while Indore should see incremental margin improvement.

  • ARPOB for mature assets expected to grow in line with inflation; new hospitals to see faster ARPOB growth in early years.

  • Total bed capacity expected to increase from 1,048 to approximately 2,500 with upcoming projects.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more